Wedbush Research Analysts Lower Earnings Estimates for PRAX

Key Points

• Wedbush has downgraded its earnings estimates for Praxis Precision Medicines, forecasting Q3 2025 earnings at ($3.23) per share, a decrease from the prior estimate of ($2.87).
• The company currently holds a market capitalization of $973.48 million and has a negative return on equity of 59.42% and a negative net margin of 2,137.48%.
• Despite the negative outlook from Wedbush, other analysts maintain a positive stance with multiple "buy" ratings and price targets ranging from $80.00 to $115.00.

Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) - Analysts at Wedbush cut their Q3 2025 earnings per share estimates for shares of Praxis Precision Medicines in a research note issued on Monday, August 4th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($3.23) per share for the quarter, down from their prior estimate of ($2.87). Wedbush currently has a "Underperform" rating and a $28.00 target price on the stock. The consensus estimate for Praxis Precision Medicines' current full-year earnings is ($10.22) per share. Wedbush also issued estimates for Praxis Precision Medicines' Q4 2025 earnings at ($3.24) EPS, FY2025 earnings at ($13.08) EPS, Q1 2026 earnings at ($2.00) EPS, Q2 2026 earnings at ($2.04) EPS, Q3 2026 earnings at ($2.08) EPS, Q4 2026 earnings at ($2.13) EPS, FY2026 earnings at ($8.25) EPS, FY2027 earnings at ($6.96) EPS, FY2028 earnings at ($5.54) EPS and FY2029 earnings at ($3.93) EPS.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported ($3.31) earnings per share for the quarter, topping analysts' consensus estimates of ($3.40) by $0.09. Praxis Precision Medicines had a negative return on equity of 60.07% and a negative net margin of 2,137.48%.

PRAX has been the topic of a number of other research reports. Oppenheimer upped their price target on Praxis Precision Medicines from $97.00 to $115.00 and gave the company an "outperform" rating in a research report on Tuesday, July 8th. HC Wainwright upped their target price on Praxis Precision Medicines from $105.00 to $115.00 and gave the company a "buy" rating in a research report on Tuesday, August 5th. Chardan Capital restated a "buy" rating and set a $80.00 target price on shares of Praxis Precision Medicines in a research report on Tuesday, July 29th. Finally, Needham & Company LLC restated a "buy" rating and set a $80.00 target price on shares of Praxis Precision Medicines in a research report on Thursday, June 12th. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $95.22.

Praxis Precision Medicines Price Performance

PRAX stock traded down $1.33 during midday trading on Wednesday, reaching $45.94. 438,540 shares of the stock were exchanged, compared to its average volume of 543,862. The stock has a market capitalization of $967.04 million, a PE ratio of -3.74 and a beta of 2.62. Praxis Precision Medicines has a 52 week low of $26.70 and a 52 week high of $91.83. The company has a fifty day moving average price of $48.11 and a 200 day moving average price of $48.06.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of PRAX. Cormorant Asset Management LP increased its position in shares of Praxis Precision Medicines by 3.1% during the first quarter. Cormorant Asset Management LP now owns 1,745,000 shares of the company's stock valued at $66,083,000 after acquiring an additional 51,781 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its position in Praxis Precision Medicines by 188.1% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,742,758 shares of the company's stock worth $65,998,000 after buying an additional 1,137,748 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Praxis Precision Medicines by 7.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,208,522 shares of the company's stock worth $93,008,000 after buying an additional 88,442 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Praxis Precision Medicines by 2.2% in the first quarter. Vanguard Group Inc. now owns 1,087,020 shares of the company's stock valued at $41,165,000 after purchasing an additional 23,381 shares in the last quarter. Finally, VR Adviser LLC grew its position in shares of Praxis Precision Medicines by 40.2% in the fourth quarter. VR Adviser LLC now owns 989,985 shares of the company's stock valued at $76,189,000 after purchasing an additional 283,854 shares in the last quarter. Institutional investors own 67.84% of the company's stock.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.